Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.
Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback